Combination immunotherapy: Where do we go from here? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-08-18

AUTHORS

Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson, Dario A. A. Vignali

ABSTRACT

The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against “immunologically inert” tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014. More... »

PAGES

38

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z

DOI

http://dx.doi.org/10.1186/s40425-015-0083-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040993290


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Overacre", 
        "givenName": "Abigail E.", 
        "id": "sg:person.01112462306.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112462306.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School, 02115, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.62560.37", 
          "name": [
            "Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School, 02115, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurtulus", 
        "givenName": "Sema", 
        "id": "sg:person.01337707220.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337707220.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, 06250, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, 06250, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.21107.35", 
          "name": [
            "Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pardoll", 
        "givenName": "Drew M.", 
        "id": "sg:person.012740423777.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012740423777.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School, 02115, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.62560.37", 
          "name": [
            "Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School, 02115, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anderson", 
        "givenName": "Ana", 
        "id": "sg:person.0676714763.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676714763.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vignali", 
        "givenName": "Dario A. A.", 
        "id": "sg:person.07642160524.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07642160524.60"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015-08-18", 
    "datePublishedReg": "2015-08-18", 
    "description": "The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against \u201cimmunologically inert\u201d tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40425-015-0083-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "3"
      }
    ], 
    "keywords": [
      "combination of immunotherapy", 
      "remarkable clinical success", 
      "mechanism of action", 
      "PD-1", 
      "conventional therapy", 
      "cancer immunotherapy", 
      "CTLA-4", 
      "refractory cancer", 
      "clinical success", 
      "immunotherapy", 
      "tumor types", 
      "inhibitory mechanism", 
      "patients", 
      "new inhibitory mechanism", 
      "therapy", 
      "tumors", 
      "considerable excitement", 
      "cancer", 
      "efficacy", 
      "one-day workshop", 
      "mechanism", 
      "reliable strategy", 
      "response", 
      "action", 
      "research efforts", 
      "meeting", 
      "efforts", 
      "combination", 
      "strategies", 
      "types", 
      "success", 
      "excitement", 
      "challenges", 
      "workshop", 
      "important foundation", 
      "approach", 
      "issues", 
      "outstanding challenges", 
      "foundation"
    ], 
    "name": "Combination immunotherapy: Where do we go from here?", 
    "pagination": "38", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040993290"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-015-0083-z"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-015-0083-z", 
      "https://app.dimensions.ai/details/publication/pub.1040993290"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_684.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40425-015-0083-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'


 

This table displays all metadata directly associated to this object as RDF triples.

139 TRIPLES      20 PREDICATES      63 URIs      55 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-015-0083-z schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N1b9e084e1821472888be7f2bee5ace34
4 schema:datePublished 2015-08-18
5 schema:datePublishedReg 2015-08-18
6 schema:description The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against “immunologically inert” tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.
7 schema:genre article
8 schema:isAccessibleForFree true
9 schema:isPartOf N5dec6a51575d480e9b0f0301c66cde98
10 N6bc0f12cf95f4471b85d419b5c3b891c
11 sg:journal.1049249
12 schema:keywords CTLA-4
13 PD-1
14 action
15 approach
16 cancer
17 cancer immunotherapy
18 challenges
19 clinical success
20 combination
21 combination of immunotherapy
22 considerable excitement
23 conventional therapy
24 efficacy
25 efforts
26 excitement
27 foundation
28 immunotherapy
29 important foundation
30 inhibitory mechanism
31 issues
32 mechanism
33 mechanism of action
34 meeting
35 new inhibitory mechanism
36 one-day workshop
37 outstanding challenges
38 patients
39 refractory cancer
40 reliable strategy
41 remarkable clinical success
42 research efforts
43 response
44 strategies
45 success
46 therapy
47 tumor types
48 tumors
49 types
50 workshop
51 schema:name Combination immunotherapy: Where do we go from here?
52 schema:pagination 38
53 schema:productId N72743a0cbf9548f5b97891f10f3f47df
54 Nf59c96ba58af43a0ab352addacfe9d45
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040993290
56 https://doi.org/10.1186/s40425-015-0083-z
57 schema:sdDatePublished 2022-09-02T15:59
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher Ne0587ec966c2482b917333262510444c
60 schema:url https://doi.org/10.1186/s40425-015-0083-z
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N1b9e084e1821472888be7f2bee5ace34 rdf:first sg:person.01112462306.15
65 rdf:rest N84863d8908a04415ab4bd607eb9210ff
66 N51a68135402b4f84b0533cd33fce7319 rdf:first sg:person.0706626451.72
67 rdf:rest Nce5269d82d2f44a8b9c0823b6543d3bf
68 N5dec6a51575d480e9b0f0301c66cde98 schema:volumeNumber 3
69 rdf:type schema:PublicationVolume
70 N6bc0f12cf95f4471b85d419b5c3b891c schema:issueNumber 1
71 rdf:type schema:PublicationIssue
72 N72743a0cbf9548f5b97891f10f3f47df schema:name dimensions_id
73 schema:value pub.1040993290
74 rdf:type schema:PropertyValue
75 N84863d8908a04415ab4bd607eb9210ff rdf:first sg:person.01337707220.24
76 rdf:rest N51a68135402b4f84b0533cd33fce7319
77 Nc8ef2599d67d4590b606fe87185584a4 rdf:first sg:person.07642160524.60
78 rdf:rest rdf:nil
79 Nce5269d82d2f44a8b9c0823b6543d3bf rdf:first sg:person.012740423777.12
80 rdf:rest Nf24b90b7cf8f4897a172ae12bf9b9817
81 Ne0587ec966c2482b917333262510444c schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 Nf24b90b7cf8f4897a172ae12bf9b9817 rdf:first sg:person.0676714763.05
84 rdf:rest Nc8ef2599d67d4590b606fe87185584a4
85 Nf59c96ba58af43a0ab352addacfe9d45 schema:name doi
86 schema:value 10.1186/s40425-015-0083-z
87 rdf:type schema:PropertyValue
88 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
89 schema:name Medical and Health Sciences
90 rdf:type schema:DefinedTerm
91 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
92 schema:name Oncology and Carcinogenesis
93 rdf:type schema:DefinedTerm
94 sg:journal.1049249 schema:issn 2051-1426
95 schema:name Journal for ImmunoTherapy of Cancer
96 schema:publisher BMJ
97 rdf:type schema:Periodical
98 sg:person.01112462306.15 schema:affiliation grid-institutes:grid.21925.3d
99 schema:familyName Overacre
100 schema:givenName Abigail E.
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112462306.15
102 rdf:type schema:Person
103 sg:person.012740423777.12 schema:affiliation grid-institutes:grid.21107.35
104 schema:familyName Pardoll
105 schema:givenName Drew M.
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012740423777.12
107 rdf:type schema:Person
108 sg:person.01337707220.24 schema:affiliation grid-institutes:grid.62560.37
109 schema:familyName Kurtulus
110 schema:givenName Sema
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337707220.24
112 rdf:type schema:Person
113 sg:person.0676714763.05 schema:affiliation grid-institutes:grid.62560.37
114 schema:familyName Anderson
115 schema:givenName Ana
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676714763.05
117 rdf:type schema:Person
118 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.47100.32
119 schema:familyName Sznol
120 schema:givenName Mario
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
122 rdf:type schema:Person
123 sg:person.07642160524.60 schema:affiliation grid-institutes:grid.21925.3d
124 schema:familyName Vignali
125 schema:givenName Dario A. A.
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07642160524.60
127 rdf:type schema:Person
128 grid-institutes:grid.21107.35 schema:alternateName Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
129 schema:name Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
130 rdf:type schema:Organization
131 grid-institutes:grid.21925.3d schema:alternateName Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA
132 schema:name Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA
133 rdf:type schema:Organization
134 grid-institutes:grid.47100.32 schema:alternateName Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, 06250, New Haven, CT, USA
135 schema:name Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, 06250, New Haven, CT, USA
136 rdf:type schema:Organization
137 grid-institutes:grid.62560.37 schema:alternateName Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, 02115, Boston, MA, USA
138 schema:name Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, 02115, Boston, MA, USA
139 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...